Samik Pharmaceutical Company LTD. (KOSDAQ:014950)
11,260
-750 (-6.24%)
At close: Mar 9, 2026
KOSDAQ:014950 Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Cash & Equivalents | 5,167 | 4,551 | 2,074 |
| Short-Term Investments | 8,327 | 4,327 | 2,000 |
| Trading Asset Securities | 6,043 | 4,057 | 4,692 |
| Cash & Short-Term Investments | 19,536 | 12,935 | 8,766 |
| Cash Growth | 122.86% | 47.55% | - |
| Accounts Receivable | 9,369 | 8,767 | 9,202 |
| Other Receivables | 138.82 | 146.74 | 69.57 |
| Receivables | 9,508 | 8,914 | 9,572 |
| Inventory | 15,174 | 11,982 | 9,976 |
| Prepaid Expenses | 2.15 | 2.13 | 2.44 |
| Other Current Assets | 401.68 | 295.98 | 340.98 |
| Total Current Assets | 44,621 | 34,129 | 28,658 |
| Property, Plant & Equipment | 24,850 | 24,963 | 25,389 |
| Long-Term Investments | 34 | 4,411 | 4,214 |
| Other Intangible Assets | 323.84 | 320.91 | 338.49 |
| Long-Term Accounts Receivable | - | 0 | 0 |
| Long-Term Deferred Tax Assets | 263.21 | 97.23 | 94.89 |
| Other Long-Term Assets | 188.18 | 387.51 | 337.51 |
| Total Assets | 70,343 | 64,309 | 59,032 |
| Accounts Payable | 3,986 | 1,742 | 1,490 |
| Accrued Expenses | 4,007 | 3,586 | 3,156 |
| Current Portion of Leases | 67.56 | 68.91 | 139.37 |
| Current Income Taxes Payable | 779.46 | 359.93 | 19.33 |
| Other Current Liabilities | 4,279 | 4,675 | 4,071 |
| Total Current Liabilities | 13,118 | 10,432 | 8,876 |
| Long-Term Leases | 93.52 | 23.81 | 57.15 |
| Pension & Post-Retirement Benefits | 914.26 | 37.12 | 18.47 |
| Long-Term Deferred Tax Liabilities | 1,792 | 1,778 | 1,642 |
| Other Long-Term Liabilities | 91.6 | 86.21 | 103.1 |
| Total Liabilities | 16,010 | 12,357 | 10,697 |
| Common Stock | 714.95 | 714.95 | 702.5 |
| Additional Paid-In Capital | 781.51 | 781.96 | - |
| Retained Earnings | 53,722 | 51,166 | 47,925 |
| Comprehensive Income & Other | -884.72 | -711.02 | -292.17 |
| Shareholders' Equity | 54,333 | 51,952 | 48,335 |
| Total Liabilities & Equity | 70,343 | 64,309 | 59,032 |
| Total Debt | 161.09 | 92.71 | 196.52 |
| Net Cash (Debt) | 19,375 | 12,842 | 8,570 |
| Net Cash Growth | 126.09% | 49.85% | - |
| Net Cash Per Share | 2716.50 | 1826.67 | 1220.83 |
| Filing Date Shares Outstanding | 7.16 | 7.03 | 7.02 |
| Total Common Shares Outstanding | 7.16 | 7.03 | 7.02 |
| Working Capital | 31,503 | 23,697 | 19,782 |
| Book Value Per Share | 7592.32 | 7389.69 | 6885.80 |
| Tangible Book Value | 54,010 | 51,631 | 47,997 |
| Tangible Book Value Per Share | 7547.07 | 7344.04 | 6837.58 |
| Land | 18,821 | 18,821 | 18,821 |
| Buildings | 7,755 | 7,890 | 7,884 |
| Machinery | 11,652 | 11,256 | 10,555 |
| Construction In Progress | 173.8 | 177.5 | 288.3 |
Source: S&P Capital IQ. Standard template. Financial Sources.